Labiana Health

Labiana Health Long-term Debt

The Long-Term Debt of Labiana Health (LAB.MC) as of Nov 19, 2026 is 29.81 M EUR. In the previous year, Long-Term Debt was 26.89 M EUR — a change of 10.85% (higher).

Long-term Debt

29.81 MEUR

YoY

10.85%

Last updated:

Long-Term Debt of Labiana Health is 2025 29.81 M EUR. Long-Term Debt of Labiana Health was 2024 26.89 M EUR. It decreases by 10.85% higher compared to the previous year.

The Labiana Health Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
2.82 M EUR
Jan 1, 2019
15.33 M EUR
Jan 1, 2021
23.50 M EUR
Jan 1, 2022
14.30 M EUR
Jan 1, 2023
29.68 M EUR
Jan 1, 2024
26.89 M EUR
Jan 1, 2025
29.81 M EUR
The Labiana Health Long-term Debt history
YEARLong-term DebtYoY
29.81 MEUR+10.85%
26.89 MEUR-9.40%
29.68 MEUR+107.58%
14.30 MEUR-39.14%
23.50 MEUR+53.28%
15.33 MEUR+444.47%
2.82 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Long-Term Debt of Labiana Health is 29.81 M EUR in 2025.

Long-Term Debt of Labiana Health changed from 26.89 M EUR to 29.81 M EUR, representing a 10.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labiana Health

All Key Metrics — Labiana Health